Document Detail

Recent therapeutic advances and insights of recurrent glioblastoma multiforme.
MedLine Citation:
PMID:  23276952     Owner:  NLM     Status:  MEDLINE    
Despite recent therapeutic advances, most patients with glioblastoma multiforme (GBM) experience disease recurrence, with very poor prognosis. Much work still needs to done to improve the treatment efficacy. The optimal management of patients with recurrent GBM is still controversial. This article summarizes the current status of therapeutic strategies in recurrent glioblastoma patients, with an emphasis on more novel approaches and important recent progress. The clinical evidence of current treatment strategies were collected and reviewed. Patients still need comprehensive treatment for recurrent GBM. Surgery may be useful as adjuvant treatment for patients with symptoms due to the effect of the mass or for patients requiring definitive histopathology, but it generally should be combined with another treatment modality; high-precision re-irradiation such as stereotactic radiosurgery or gamma knife is another option. Chemotherapy like fotemustine, or a metronomic schedule of temozolomide regimens and anti-angiogenic agents like bevacizumab could also be considered. Other targeted molecular inhibitors or anti-angiogenic therapies, and immunotherapies are still under investigation and their efficacy needs to be evaluated further in the future.
Juxiang Chen; Tao Xu
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-01
Journal Detail:
Title:  Frontiers in bioscience (Landmark edition)     Volume:  18     ISSN:  1093-4715     ISO Abbreviation:  Front Biosci (Landmark Ed)     Publication Date:  2013  
Date Detail:
Created Date:  2013-01-01     Completed Date:  2013-06-12     Revised Date:  2013-07-29    
Medline Journal Info:
Nlm Unique ID:  101612996     Medline TA:  Front Biosci (Landmark Ed)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  676-84     Citation Subset:  IM    
Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, No. 415 Fengyang Road, Shanghai, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use
Antigens, Neoplasm / immunology
Antineoplastic Agents / therapeutic use*
Brain Neoplasms / drug therapy*,  surgery
Combined Modality Therapy
Dacarbazine / analogs & derivatives*,  therapeutic use
Dideoxynucleosides / diagnostic use
Glioblastoma / drug therapy*,  surgery
Interleukin-13 Receptor alpha2 Subunit / immunology
Neoplasm Recurrence, Local / drug therapy*,  surgery
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/Antigens, Neoplasm; 0/Antineoplastic Agents; 0/Dideoxynucleosides; 0/Interleukin-13 Receptor alpha2 Subunit; 2S9ZZM9Q9V/bevacizumab; 4342-03-4/Dacarbazine; 85622-93-1/temozolomide; PG53R0DWDQ/alovudine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  ROS signaling pathways and biological rhythms: perspectives in crustaceans.
Next Document:  Homocysteine induces inflammatory transcriptional signaling in monocytes.